natgillin/translations-raw huggingface dataset:
An ORC apparatus for generation of electric energy by organic Rankine cycle, comprising: 
PATENTNI ZAHTJEVI ORC uređaj za dobivanje električne energije organskim Rankineovim ciklusom, koji sadrži:
0.5% of SLS by weight of the composition; 
mas% SLS, u odnosu na masu pripravka;
Naturally, the mechanical catch described is not the only item of its kind that can be made since, for this purpose, it is also possible to develop bosses or fins or teeth that are equally efficient. 
Naravno da mehaničko zahvaćanje koje je opisano nije jedina izvedba koja se može uraditi, budući da je za tu namjenu moguće također razviti čepove ili peraje ili zupce koji su jednako tako učinkoviti.
and the 90th percentile of the particle size distribution has a diameter of less than or equal to 9.0 µm. 
1 90. percentil distribucije veličine čestica ima promjer od manje od ili jednak 9,0 um.
A method of vaccinating an animal comprising at least one administration of the composition or vector of any one of paragraphs 1-30. 
Sastav ili cjepivo za uporabu prema bilo kojem od zahtjeva 1-6, naznačen/o time, da rekombinantni vektor Gallid herpesvirusa-3 obuhvaća promotor.
Any of the above embodiments are also embodiments of formula IC with the proviso that R8 does not exist in compounds of general formula IC. 
Bilo koji od oblika koji su gore navedeni također predstavljaju oblike formule IC pod uvjetom da R* ne postoji u spojevima opće formule IC.
amplification of a region of the pp38 gene within the nucleic acid sample of (i), said region containing a consistent single nucleotide polymorphism (SNP) difference between vaccine and virulent strains of MDV-1; and 
(a) amplificiranju područja u genu pp38 u uzorku nukleinske kiseline iz koraka (i), gdje navedeno područje pokazuje razliku u konzistentnom jednonukleotidnom polimorfizmu (SNP) između cjepivnih i virulentnih sojeva MDV-1, gdje se navedeni SNP G/A polimorfizam nalazi na položaju 320 u sljedovima na Slici 1 (Ca)i (bi
The slurry of claim 1 or 2 wherein the aluminum or aluminum alloy powder comprises a particle size distribution characterized in that the 50th percentile of the particle size distribution has a diameter of between about 3.9 to 4.5 microns and the 90th percentile of the particle size distribution has a diameter of less than or equal to about 9.0 microns. 
Suspenzija prema bilo kojem od zahtjeva 1 do 2 pri čemu aluminijev prah ili prah aluminijeve legure ima distribuciju veličine čestica, naznačena time što 50. percentil distribucije veličine čestica ima promjer od između 3,9 do 4,5 um. 1 90. percentil distribucije veličine čestica ima promjer od manje od ili jednak 9,0 um.
Method according to any one of the preceding claims, characterized in that the calcium carbonate of said carbonate-comprising material is a precipitated calcium carbonate (PCC), a natural ground calcium carbonate (NGCC), a surface-reacted calcium carbonate (SRCC), or a mixture thereof. 
Uporaba u skladu s bilo kojim od prethodnih patentnih zahtjeva, karakterizirana na način da je navedeni materijal koji sadrži kalcijev karbonat istaloženi kalcijev karbonat (PCC), prirodna ruda kalcijevog karbonata (NGCC), površinski-izreagirani kalcijev karbonat (SRCC) ili njihova smjesa.
the single nucleotide polymorphism marker having a G at the position corresponding to position 286 in SEQ ID NO:3, 
rain jednostrukog nukleotida koji ima G na položaju koji odgovara položaju 286 u SEQ h)
The method of claim 3, wherein the pirfenidone is administered three times per day with food. A method of administering pirfenidone to treat a patient with idiopathic pulmonary fibrosis (IPF), said patient having exhibited an increase of about 2.5-fold to about 5-fold, compared to the upper limit of normal, in one or more biomarkers of liver function after a first pirfenidone administration, comprising providing to said patient a second administration of pirfenidone, comprising (a) administering to said patient pirfenidone at a dose of at least 1600 mg/day. 
Upotreba pirfenidona u proizvodnji lijeka za liječenje pacijenta s idiopatskom pulmonarnom fibrozom (IPF), pri čemu pacijent ima razinu 2 abnormalnosti u jednom ili više biomarkera funkcije jetre poslije davanja pirfenidona, i ima abnormalnu razinu alanin transaminaze (ALT) i/ili aspartat transaminaze (AST) koji je više od 2.5- do 5- puta povećana u usporedbi s gornjom granicom normalnih vrijednosti, poslije davanja pirfenidona, gdje (a) spomenutom pacijentu je davan pirfenidon u dozama od bar 1600 mg/dnevno ili 1602 mg/dnevno.
The method of claim 1, wherein step (b) is performed within a period of not more than about 96 hours after step (a) of administration of the fluorescent conjugate to the patient. 
(Cc) osvjetljavanje tkiva na mjestu resekcije pacijenta koji se podvrgava operaciji resekcije sa svjetlošću valne duljine 660 do 700 nm, pri čemu se stupanj (b) izvodi u periodu od najviše 96 sati nakon koraka (a).
A compound of formula (IIIC): 
Spoj formule (II):
The compounds (especially in the acid form) are very potent inhibitors, typically selective inhibitors, of GST P1-1 in vitro. 
Spojevi (posebno u obliku kiseline) su inhibitori, tipično selektivni inhibitori, GST P1-1 in vitro.
A pharmaceutical composition according to claim 20 for use in treating: a CNS disorder; eating disorders; obesity; compulsive gambling; sexual disorders; narcolepsy; sleep disorders; diabetes; metabolic syndrome; schizophrenia; schizo-affective conditions; Huntington's disease; bipolar disorders; dystonic conditions; or tardive dyskinesia in a human in need thereof; or for use in smoking cessation treatment in a human in need thereof. 
Farmaceutski pripravak prema zahtjevu 20 koji se koristi za liječenje: poremećaja funkcije središnjeg živčanog sustava; poremećaja u prehrani; pretilosti, kompulzivnog kockanja, seksualnih poremećajdN narkolepsije; poremećaja sna; šećerne bolesti; metaboličkog sindroma, šizofrenije; šizo-afektivnih stanja; Huntingtonove bolesti; bipolarnog poremećaja; distoničnih stanja; tardivne diskinezije kod ljudi kojima je taj pripravak potreban; ili se koristi za liječenje ljudi koji se odriču pušenja a koji za istim imaju potrebu.
A protein comprising (i) an elastase activation sequence comprising an elastase recognition sequence operably linked to (ii) the amino acid sequence of a mature elastase. 
zreli tip I elastaza je zreli tip svinjske I elastaze, koji opcionalno sadrži sekvencu aminokiseline koja ima:
Alternatively, necessary starting materials are obtainable by analogous procedures to those illustrated which are within the ordinary skill of an organic chemist. 
Alternativno, potrebni polazni materijali su pribavljivi postupcima analognim prikazanim, koji su u okviru uobičajene vještine organskog kemičara.
The resulting precipitated is collected by filtration and dried under high vacuum to yield the titled compound as a yellow powder. 
Dobiveni talog se skupi s filtracijom i osuši pod visokim vakuumom, čime se dobije naslovni spoj kao žuti prah.
A pilot valve arrangement according to any one of the preceding claims, wherein said first pilot valve part further comprises: 
Sklop (301) pilot ventila prema bilo kom od prethodnih zahtjeva, pri čemu navedeni prvi dio (101) pilot ventila dalje sadrži:
Use according to any one of the preceding claims, characterized in that said 2-((1-methylpropyl)amino)ethanol is added to the dry form of said calcium carbonate-comprising material, and is optionally dry ground therewith before forming said suspension of calcium carbonate-comprising material. 
Uporaba u skladu s bilo kojim od prethodnih patentnih zahtjeva, karakterizirana na način da je navedeni 2-((1- metilpropil)amino)etanol dodan suhom obliku materijala koji sadrži kalcijev karbonat i prema izboru je pored toga potpuno osušen prije stvaranja navedene otopine materijala koji sadrži kalcijev karbonat.
A cell comprising the nucleic acid according to claim 12 or the vector according to claim 13. A method for the preparation of the biologically active protein according to any one of claims 1 to 10 comprising culturing the cell according to claim 14 and isolating said biologically active protein from the culture. 
Postupak priprave biološki aktivnog proteina u skladu s bilo kojim od patentnih zahtjeva 1 do 10, naznačen time što se sastoji u uzgajanju stanica u skladu s patentnim zahtjevom 14 u kulturi i izoliranju navedenog biološki aktivnog proteina iz kulture.
However, insight can vary between individuals and throughout the duration of the psychotic episode. 
Naravno, uvid u stanje varira ovisno o pojedincu i kroz vrijeme trajanja psihotične epizode.
providing an increased pressure in the pressure chamber; 
- < osiguranje povećanog pritiska u tlačnoj komori;
The composition of claim 1 wherein the composition is suitable to be applied to a plant substrate. 
Pripravak u skladu s patentnim zahtjevom 1, naznačen time što je pripravak pogodan za primjenu na biljnom supstratu.
For example, a disclosed pharmaceutically acceptable composition may include the ascorbic acid or a pharmaceutically acceptable salt thereof is sodium ascorbate, e.g., about 0.25% by weight or more ascorbic acid or a pharmaceutically acceptable salt thereof, about 0.2% to about 3% by weight ascorbic acid or a pharmaceutically acceptable salt thereof, or about 0.5% to about 1% by weight ascorbic acid or pharmaceutically acceptable salts thereof. 
HR P20180514 T1 PATENTNI ZAHTJEVI Farmaceutski prihvatljiv tekući sastav sadržeći 2,5% do 7% masenog udjela levodopa; do 2% masenog udjela karbidopa; 5% do 18% masenog udjela arginina; i 0,25% do 3% masenog udjela askorbinske kiseline ili farmaceutski prihvatljive soli iste, naznačeno time da spomenuti sastav ima pH vrijednost od 9,1 do 9,8 na 25", te je molarni omjer levodopa sa karbidopom u odnosu na arginin 1:1,8 do 1:3,5.
A stirred solution of intermediate 37 (5.1 g, 0.03 mol) and 3.3 g triethylamine in 100 mL CH2Cl2 under N2 was treated with di-t-butyl dicarbonate (7.2 g, 0.033 mol) portionwise and stirred at room temperature for 30 min. 
Miješana otopina Intermedijera 37 (5.1 g, 0.03 mol) 1 3.3 g trietilamina u 100 mL CH2CL, pod N, tretirana je sa di-t-butil dikarbonatom (7.2 g, 0.033 mol) u dijelovima 1 miješana je na sobnoj temperaturi 30 minuta.
(Ex. 26). A compound according to claim 1, selected from compounds of the following formulae, or a pharmaceutically acceptable salt thereof: 
Spoj u skladu sa patentnim zahtjevom 1, odabran od spoja sa sljedećim formulama, ili farmaceutski prihvatljiva sol istog:
The anti-IL-5 antibody for the use as claimed in claim 1, wherein said composition comprising the antibody is to be administered intravenously. 
Protutijelo protiv IL-5, namijenjeno upotrebi u skladu s patentnim zahtjevom 1, naznačeno time što navedeni pripravak koji sadrži protutijelo treba primijeniti intravenski.
The starting compound may be converted into a first taxane analog of formula wherein and R2 are each selected from H, an alkyl group, an olefinic group, an aromatic group, an O-alkyl group, an O-olefinic group, and an O-aromatic group; 
Početni spoj se može pretvoriti u prvi analog taksana formule LE. pri čemu R; i R> su, svaki, odabrani od H, alkil skupine, olefin skupine, aromatske skupine, O-alkil skupine, O-olefin skupine ili O-aromatske skupine;
The process according to any one of Items 14a to 16, wherein the spraying in step (e) or (e'-1) is either spraying at a low temperature for freezing or spraying under reduced pressure for freezing. 
Postupak prema zahtjevu 14, naznačen time da raspršivanje u koraku (€'-1) je ili raspršivanje kod niske temperature radi smrzavanja ili raspršivanje pod sniženim tlakom radi smrzavanja.
reacting a compound of Formula III with a compound having the Formula IV in the presence of an organo hypervalent iodine reagent; or 
NHNH2 sa spojem Formule IV u prisutnosti organo hipervalentnog reagensa joda; ili (c) za spoj Formule I gdje A je OR", spajanje odgovarajućeg spoja Formule V
The method of any one of clauses 1-20, wherein the frequency of an immediate post injection reaction or the frequency of an injection site reaction is reduced relative to daily subcutaneous administration of 20mg glatiramer acetate. 
Lijek za uporabu prema patentnom zahtjevu 1 ili glatiramer acetat za uporabu prema patentnom zahtjevu 2, naznačeni time, da je učestalost reakcije neposredno nakon injekcije ili reakcije na mjestu uboda smanjena u odnosu na učestalost pretrpljenu uz dnevno supkutano davanje od 20 mg glatiramer acetata.
is phenyl substituted with one to three R41 substituents independently selected from the group consisting of (C1-3)alkyl, (C1-3)alkoxy, phenyl(C1-3)alkoxy, hydroxy, C1-6alkylaminocarbonyl, and aminocarbonyl; provided that no more than one R41 is aminocarbonyl, C1-6alkylaminocarbonyl, hydroxy, or a phenyl-containing substituent; is hydrogen; Ra and Rb are independently hydrogen or methyl; 
Crsalkilaminokarbonil; (C;.4alkil)aminokarbonil; heterociklilkarbonil pri čemu heterociklil je 5-7 člani prsten koji sadrži dušik i navedeni heterociklil je spojen na karbonil ugljik preko atoma dušika; karboksi; i cijano: uz uvjet da ne više od jedan R'' supstituent je formilamino, aminokarbonil, C,yalkilaminokarbonil, (Crgalkil),aminokarbonil, heterociklilkarbonil, hidroksi, karboksi ili supstituent koji sadrži fenil; je vodik ili metil;
The method of claim 5, wherein the matrix comprises one or more of transforming growth factor beta (TGF-beta), epidermal growth factor (EGF), insulin-like growth factor 1, bovine fibroblast growth factor (bFGF), and/or platelet-derived growth factor (PDGF). 
Postupak u skladu s patentnim zahtjevom 5, naznačen time što matriks sadrži jedan ili više od transformirajućeg čimbenika rasta B (TGFPB), čimbenika rasta epiderme (EGF), inzulinu sličnog čimbenika rasta 1, goveđeg čimbenika rasta fibroblasta (bFGF), i/ili čimbenika rasta iz trombocita (PDGF).
in which Z1, R1 and R2 have the meaning given in claim 1, which cyclize already under these reaction conditions or in a subsequent reaction step under the influence of a base to give the compounds of the formula (I) wherein R3 represents hydrogen. 
(IV-A) gdje Z', R' i R* imaju gore navedena značenja, koji cikliziraju već u ovim reakcijskim uvjetima ili u koraku naknadne reakcije pod utjecajem baze kako bi se dobili spojevi formule (I) pri čemu R* predstavlja vodik.
A combined preparation comprising a GPR119 agonist and a DPP-IV inhibitor for simultaneous, separate or sequential use for the treatment of diabetes or a condition related thereto, wherein said DPP-IV inhibitor is not identical to 1-[2-[5-cyanopyridin-2-yl)amino]ethylamino]acetyl-2-cyano-(S)-pyrrolidine (NVP-DPP728). 
Postupak priprave farmaceutskog pripravka, naznačen time, da navedeni postupak obuhvaća miješanje GPRI19 agonista i DPP-IV inhibitora skupa s barem jednom farmaceutski prihvatljivom podlogom, pri čemu navedeni DPP- IV inhibitor nije identičan s 1-[2-[(5-cijanopiridin-2-iljamino jetilamino |acetil-2-cijano-(S)-pirolidinom (NVP- DPP728).
No pressure has yet been applied to the pressure chamber 8. 
U tlačnoj komori $ još nema pritiska.
said polynucleotide is codon-optimized. 
(1i) spomenuti polinukleotid je kodon-optimiziran.
wherein the antibody or fragment comprises a variable light chain (VL) in which CDR2 comprises or consists of the amino acid sequence: 
Xje Kili Hili Dili Gili N pri čemu protutijelo ili fragment sadrži varijabilni laki lanac (VL) u kojem CDR2 sadrži ili se sastoji od sekvence amino kiselina:
The composition to be administered will, in any event, contain a therapeutically effective amount of a compound of the invention, or a pharmaceutically acceptable salt thereof, for treatment of a disease-state in accordance with the teachings of this invention. 
Uporaba spoja prema zahtjevu 1, ili njegove farmaceutski prihvatljive soli, naznačena time, da je za proizvodnju lijeka za liječenje bolesti ili poremećaja povezanih sa nekontroliranim, nenormalnim i/ili neželjenim staničnim djelovanjima.
The method of clause 7, wherein said compound of Formula I is administered after the daily dosage of atypical antipsychotic. The method of clause 1, wherein said compound of Formula I is administered to the patient prior to the onset of the antipsychotic induced weight gain. 
Spoj za uporabu sukladno patentnom zahtjevu 1, naznačeno time da je navedeni spoj primjenjivan kod pacijenta prije početka dobivanja na težini induciranog antipsihoticima ili gdje je navedeni spoj primjenjivan na početku pacijentovog netipičnog antipsihotičnog tretmana.
A method for treating or preventing a bacterial infection or bacterial colonization in a subject comprising administering to the subject an effective amount of a compound of claim 1, or a pharmaceutically acceptable salt thereof. The method of claim 5, wherein the infection is caused by a Gram-positive organism. The method of claim 6, wherein the Gram-positive organism is selected from the class Bacilli; phylum Actinobacteria; and class Clostridia. 
Spoj prema bilo kojem od zahtjeva 1-4, ili njegova farmaceutski prihvatljiva sol, ili farmaceutski pripravak prema zahtjevu 5, naznačen time što se koristi za liječenje ili prevenciju infekcije ili kolonizacije kod subjekta. Spoj za uporabu prema zahtjevu 6, naznačen time što: (a) infekcija je uzrokovana organizmom koji raste unutar stanice kao dio procesa infekcije;
In an even more preferred embodiment of the pharmaceutical methods of the invention, the CD19xCD3 bispecific single chain antibody construct is to be administered in a daily dose of 15µg, 30µg, 60 µg or 90 µg per square meter patient body surface area. 
Konstrukt namijenjen upotrebi u skladu s bilo kojim od patentnih zahtjeva 1 do 13, naznačen time što CD19xCD3 bispecifično jednolančano protutijelo kao konstrukt treba primijeniti u dnevnoj dozi od 15 ug do 30 ug/m' tjelesne površine pacijenta.
Therefore, to be able to meet the demand a large number of kegs must be in circulation causing storages of plenty of empty kegs during periods of low consumption. 
Zbog toga, da bi se moglo udovoljiti potražnju, u optoku mora biti veliki broj bačava, što tijekom perioda niske potrošnje uzrokuje skladištenje mnogo praznih bačava.
50 20 A composition suitable for control of diseases caused by phytopathogens comprising a synergistically effective amount of (A) a compound of formula I 
Pripravak koja je pogodan za kontrolu bolesti koje uzrokuju fitopatogeni, naznačen time što sadrži (A) spoj formule (I)
By altering the reaction conditions, both the 31- and 42-hydroxyl groups can be similarly activated. 
Promjenom reakcijskih uvjeta obje grupe, i 31- i 42-hidroksilna grupa mogu se aktivirati na sličan način.
Blood was collected at 5, 10, 15 and 20 minutes, and BSP content in plasma was determined with a spectrophotometer. 
Krv je uzeta nakon 5, 10, 15 i 20 minuta, a količina BSP u plazmi određena je pomoću spektrofotometra.
A system according to claim 7, wherein the system comprises a multi-buoy mooring system (7) to which a floating structure (1) can be moored such that the floating structure (1) is non-weathervaning. 
Sustav u skladu s patentnim zahtjevom 7, naznačen time, što sustav obuhvaća sustav za sidrenje s više bova (7) na koji se može vezati plutajuća struktura (1) tako da je plutajuća struktura (1) neuočliva.
Process according to claim 21 or 22, characterised in that step f) is followed by step g) of treating the liquid fraction of step f) with an acid to reduce the pH of this liquid fraction by at least 0.5 pH units, and preferably of at least 1 pH unit. 
Proces prema zahtjevu 21 ili 22, naznačen time što se u koraku g) tekuća frakcija iz koraka f) obrađuje kiselinom radi snižavanja pH te tekuće frakcije za barem 1 pH jedinicu.
The method according to claim 10, wherein the corresponding relationship between the uplink resource index and at least one uplink subframe is established by the following means: 
Postupak prema zahtjevu 1, naznačen time da se nadalje sastoji od: primanja, na korisničkom terminalu, odobrenja uzlazne veze koje prenosi indeks resursa za uzlaznu vezu;
A closing system as claimed in claim 1, characterized in that the block (21a-24a) has its major side almost equal to the width of the groove (38) and is provided with rounded potions (70, 71) art diagonally opposite vertices thereof to enable rotation, during mounting, until the operating position transverse to the groove is reached. 
Sustav za zatvaranje u skladu s patentnim zahtjevom 1, naznačen time što veća strana bloka (214-244) je gotovo jednaka širini žlijeba (38) i sadrži zaobljene dijelove (70, 71) na svojim dijagonalno nasuprotnim vrhovim kako bi se omogućilo zakretanje, tijekom ugradnje, dok se ne postigne radni položaj poprečan u odnosu na žlijeb.
In this embodiment, the aerosol generating means 30 has a thermally stable conductive carbonaceous substrate, such as a plug of porous carbon, which is impregnated with an aerosol forming substance or substances. 
U ovoj realizaciji, sredstvo 12 za generiranje aerosola uključuje termički stabilan provodljiv ugljični supstrat 30, kao što je čep od poroznog ugljika, koji je impregniran sa supstancom ili supstancama za formiranje aerosola.
A number of variations and modifications of the disclosure can be used. 
28.06.2017. (97) Broj objave europskog patenta:
coleseed oil, in stead of butter, a further reduction in fat to 30% can be obtained. 
repičinog ulja, može se količina masnoća smanjiti i na 30 %.
The composition of claim 4, wherein the CH3 domain of the 2nd antibody heavy chain of the one antibody comprises the substitution of the amino acid residue at position 368 according to the EU numbering system by a glutamic acid (E) residue. 
Postupak u skladu s patentnim zahtjevom 1 ili 2, naznačen time što navedeni prvi polipeptidni lanac koji sadrži CH3 domenu dalje sadrži ostatak lizina (K) na aminokiselinskom položaju 351 u skladu s EU sustavom numeracije.
The antibody or antibody fragment according to claim 11, wherein the disease is selected from the group consisting of: a TH2-mediated disease, an IL-4 and/or IL-13 mediated disease, an allergic disease, asthma, cancer, an autoimmune disease, a disease associated with abnormal production of IL-4 and/or IL-13, scleroderma and idiopathic pulmonary fibrosis. 
Humanizirano bispecifično protutijelo za uporabu prema zahtjevu 10, naznačeno time da je bolest odabrana iz skupine koju čine alergijska bolest, astma, rak, autoimuna bolest, skleroderma i idiopatska plućna fibroza.
A solution of an intermediate 17 (9.3 g, 25 mmol) in xylenes (150 mL) was refluxed for 18 h. 
Otopina Intermedijera 17 (9.3 g, 25 mmol) u ksilenima (150 mL) je refluksirana 18 sati.
The coated steel structure according to claim 1, wherein the thermoplastic resin is at least one selected from the group consisting of copolymers and terpolymers of a methacrylate monomer. 
Formulacija premaza prema zahtjevu 1, naznačena time što je jedna polimerna komponenta odabrana iz skupine koju čine termoplastične smole.
• a return line (112") of the preheating fluid from the die to the second tank (111) through said three-way valve (EV5). 
povratnu liniju (1127) tekućine za prethodno zagrijavanje iz kalupa u drugi spremnik (111) kroz trokraki ventil (EVS5).
filtration step: filtering the mixture of extraction to obtain a filtrate, 
filtriranja smjese na temperaturi od najmanje 65 °C kako bi se dobilo filtrat,
A saturated aqueous solution of sodium hydroxide (250 mL) was slowly added and the unclear solution was extracted with ethyl acetate (3×450 mL). 
Polako je dodana zasićena vodena otopina na trija vng hidrckslda (250 mL) i mutna otopina je ekstrahirana etil acelalom (3 x 450 mL).
A process according to claim 11 wherein the compound of formula (VI b) is prepared by treating a compound of formula (VI a) wherein X represents a leaving group, first with a nucleophilic agent and then with a "solvolytic" base. 
5 12. Postupak u skladu sa zahtjevom 11, naznačen time, da je spoj formule (VI b) pripravljen tretiranjem spoja formule (VI a)
A nucleic acid, exclusively encoding a peptide according to any one of Claims 1 to 6. 
Nukleinska kiselina koja se sastoji od niza koji kodira peptid prema jednom od Zahtjeva 1 do 3.